We are developing and commercializing precision medicine technologies to support personalized selection of treatment.
We have successfully commercialized the technologies for canine lymphoma, and have successfully developed prototype technologies for the following diseases:
We have developed, patented, and published the technology, namely NDMM-1, capable of predicting each NDMM patient’s response and/or survival following the first-line treatment based on one of the following regimens:
The technology utilizes AI to predict the probability of early disease progression, which enables stratification of the patients into the high vs low risk subgroups. Accordingly, longer survival is expected when an NDMM patient is treated by the therapy to which he or she is low risk to.
We are currently filing approvals for the technology in order to provide the service in S. Korea, the U.S., and other countries. We are also developing NDMM-2, which can support personalized optimization of melphalan dosage for transplant eligible NDMM.
We have developed, patented, and are in the process of publishing technology, namely AML-1. The technology utilizes the patient-derived cancer cells’ sensitivity to 21 anti-cancer drugs, which enables predicting his or her response and/or survival following the treatment by one of the two regimens:
The technology utilizes AI to predict the probability of early disease progression, which enables stratification of the patients into the high vs low risk subgroups. Accordingly, longer survival is expected when an AML patient is treated by the therapy to which he or she is low risk to.
We will be presenting about AML-1 in conferences starting the last quarter of 2023, and file for approval in S. Korea and international regions with the hope of providing the commercial service by 2025.
We have developed, patented, and are in the process of publishing technology, namely NHL-1. The technology utilizes the patient-derived cancer cells’ sensitivity to 18 anti-cancer drugs, which enables predicting his or her response and/or
survival following the standard treatment for the two subtypes:
The technology utilizes AI to predict the probability of early disease progression, which enables stratification of the patients into the high vs low risk subgroups. Accordingly, longer survival is expected for the low risk subgroup as shown in below.
We will be presenting about NHL-1 in conferences starting the last quarter of 2023, and file for approval in S. Korea and international regions with the hope of providing the commercial service by 2025.
